Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Australian biotech Starpharma (SPL) has launched its VivaGel BV product in the Central and Eastern European (CEE) region
  • VivaGel BV will be available over-the-counter, meaning a doctor visit or prescription won’t be required to obtain the product
  • VivaGel BV is a non-antibiotic topical treatment used to prevent the reoccurrence of bacterial vaginosis
  • The company is now looking to launch this product in other European countries
  • Starpharma is sitting 7.73 per cent in the green and shares are currently trading for $1.05 each

Australian biotech Starpharma (SPL) has launched its VivaGel BV product in the Central and Eastern European (CEE) region.

This launch follows launches in Germany, the United Kingdom, and several other European countries.

VivaGel BV will be available over-the-counter, meaning a doctor visit or prescription won’t be required to obtain the product.

The launch into the CEE is a significant opportunity for Starpharma, as it says more than 45 million women will benefit from it.

“We are excited to see VivaGel BV being rolled-out through Europe and the marketing and launch activities being undertaken by Mundipharma,” Starpharma CEO Dr Jackie Fairley commented.

“It’s been particularly pleasing to have both teams collaborating so successfully on launch and regulatory activities, and we look forward to supporting Mundipharma in its preparations for upcoming launches,” she said.

VivaGel BV is a non-antibiotic topical treatment used to prevent the reoccurrence of bacterial vaginosis (BV).

One in three women will experience BV in their lifetime, while half of these will have recurring BV.

It is the most common vaginal condition in the world and is twice as common as thrush.

“VivaGel BV is fast-becoming a trusted brand, based on its quality and effectiveness as a treatment for BV,” Mundipharma CEO Raman Singh said.

“We are delighted to be able to deliver this product to women in easter and central Europe through our extensive marketing and distribution network,” he added.

VivaGel BV is now available in the U.K. at Betafem BV Gel, BETADINE BV Gel in Europe and Asia, and Fleurstat BVgel in Australia.

Starpharma is sitting 7.73 per cent in the green and shares are trading for $1.05 each at 12:34 pm AEST.

SPL by the numbers
More From The Market Herald

" Rhinomed (ASX:RNO) receives ethics approval for Rhinoswab trial

Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in
Anteris Technologies (ASX:AVR) - CEO, Wayne Paterson

" Anteris Technologies (ASX:AVR) eyes $5m for DurAVR

Anteris Technologies (AVR) has placed 625,000 new ordinary shares to Melbourne-based global investor L1 Capital to raise $5 million.
Atomo Diagnostics (ASX:AT1) - Managing Director, John Kelly

" Atomo (ASX:AT1) approved to supply and advertise HIV Self-Test

Atomo Diagnostics (AT1) can now supply its HIV self-test to a greater variety of organisations and begin advertising thanks to recent changes made
Starpharma (ASX:SPL) - CEO, Dr Jackie Fairley

" Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Starpharma (SPL) has penned an initial deal to distribute and supply its VIRALEZE antiviral nasal spray in Vietnam.